• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Can a One-Week Naltrexone Detox Reduce Outpatient Opioid Relapse Rates?

Can a One-Week Naltrexone Detox Reduce Outpatient Opioid Relapse Rates?

May 1, 2017
Kirsten Pickard, BA
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Kirsten Pickard, BA Ms. Pickard has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: Sullivan M et al, Am J Psychiatry 2017; Epub ahead of print.

Study Type: Randomized, open-label, parallel-groups trial

Naltrexone is an opioid blocker that is FDA-approved for the treatment of alcoholism. However, it is also effective off-label for treating opioid use disorder. The medication comes in two forms: an oral pill (brand name ReVia) and an injectable version (XR naltrexone, or Vivitrol). XR naltrexone is composed of 380 mg of naltrexone, given as an intramuscular injection once a month. During that month, patients who try to use opioids will feel little if any high. This works well to prevent relapse if patients keep getting the shot.

However, it is challenging to get patients started on XR naltrexone. If they are actively using, the injection will put them into an immediate and very unpleasant withdrawal. So a common approach is to first give these patients a tapering dose of buprenorphine for a week, and then to wait a second week to completely wash out any last molecules of opioids in their bloodstream. The problem is that this 2-week delay leads to high rates of attrition and relapse, especially in outpatients. In this study, Sullivan and colleagues compared the standard 2-week delay with a rapid 7-day detox protocol using oral naltrexone as a bridge to injectable ­naltrexone.

Researchers recruited 150 patients with opioid dependence from an outpatient research clinic, of which 36.7% were primarily prescription opioid users. Participants, who were mostly male (86%), Caucasian (64%), and around 35 years old (SD 11.4), were randomly assigned to either a 1-week naltrexone detox or a 2-week buprenorphine taper/washout. In both arms, participants didn’t use for 12–24 hours and arrived at the clinic on day 2 in mild to moderate withdrawal. Both treatment arms received up to 8 mg buprenorphine on the first day to ease withdrawal symptoms. The naltrexone group (N = 98) received scheduled doses of clonidine and clonazepam on days 3–8, then oral naltrexone titrated from 1 mg to 25 mg over days 4–7. On day 8, they received a 380 mg injection of XR naltrexone. The buprenorphine group (N = 52) received a typical 7-day buprenorphine taper followed by a 7-day washout period, during which they were given ancillary comfort medications as needed. On day 15, participants who tolerated a 0.8 mg test dose of oral naltrexone received the XR naltrexone shot.

After getting XR naltrexone, participants in both groups received 4 weeks of outpatient treatment, including weekly medical visits, biweekly therapy, and urine toxicology screens at each visit. In the fifth post-induction week, participants were offered a second dose of XR naltrexone and referrals to continue treatment in community programs as warranted.

 

Results
Patients randomized to the 1-week detox were more likely to get the injection without relapsing (56.1% made it) than those in the 2-week detox group (only 32.7% made it). But among those who received XR naltrexone (56), 89.1% of the 1-week group and 82.4% of the 2-week group received a second injection, demonstrating that participants didn’t find the rapid detox aversive enough to refuse the second injection. Overall, 50% of the full naltrexone group received the second injection compared to 26.9% of the buprenorphine group.

 

CATR’s Take
The rapid 1-week naltrexone detox seems to be the better method of getting patients to start the injectable XR naltrexone treatment. Many patients (29%) in the buprenorphine arm relapsed during the 1-week washout period.

 

Practice Implications
If you have opioid-addicted patients who want to try XR naltrexone to prevent relapse, consider this rapid 1-week technique, which allows you to avoid a washout period entirely.
Addiction Treatment
KEYWORDS addiction psychopharmacology research-update substance-abuse
    Kirsten Pickard, BA

    Is Topiramate a Silver Bullet for Those Dually Dependent on Alcohol and Nicotine?

    More from this author
    www.thecarlatreport.com
    Issue Date: May 1, 2017
    SUBSCRIBE NOW
    Table Of Contents
    Take The CME Post-Test for Recovery, CATR, May 2017
    Eight Strategies to Help Patients Maintain Recovery
    Recognizing and Reversing Relapse
    Treatment vs. Recovery
    Can a One-Week Naltrexone Detox Reduce Outpatient Opioid Relapse Rates?
    Is Topiramate a Silver Bullet for Those Dually Dependent on Alcohol and Nicotine?
    DOWNLOAD NOW
    Featured Book
    • OUDFB1e_Cover_Binding.png

      Treating Opioid Use Disorder—A Fact Book (2024)

      All the tools you need to assess and treat patients struggling with opioid use disorder. 
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.